POLE and cancer: To examine the similarity of our PER-seq measurements to mutations in patients with cancer, we compared the PER-POLE-P286R error signature to the mutational profiles of over 16,000 cancer samples (comprising 13,408 whole-exome and 2,804 whole-genome sequencing (WGS) samples) from the International Cancer Genome Consortium (ICGC) database and other sources24,42.